en · de · es · fr · pt
glossary-desk.peptides7501.com › Topic › Sr9009 Background And Mechanism — Background and Details

Sr9009 Background And Mechanism — Background and Details

By Editorial Desk · published 2026-05-18 · last reviewed 2026-06-10 · Topic

The short version of REV-ERB agonist fits in a sentence. The long version — which is the one that helps — is below.

This page was last updated on 2026-06-10 and is reviewed periodically as new material appears.

SR9009 Background and Mechanism

In rodent studies, SR9009 has been reported to increase mitochondrial content in skeletal muscle and improve exercise endurance under some conditions. These findings led to popular descriptions such as an exercise mimetic, although that term oversimplifies the biology. Effects vary by dose, timing, tissue, and model. The compound's influence on circadian pathways means that time of administration can matter in experiments. Whether similar metabolic changes occur in humans remains largely unexplored in controlled published trials.

Pharmacokinetic data for SR9009 are limited in published literature. Some reports indicate low oral bioavailability and rapid clearance in animals, which complicates interpretation of exposure and effect. Researchers often use injected routes in preclinical work to achieve measurable systemic levels. Analytical studies rely on mass spectrometry to detect the parent compound and its metabolites. Questions about tissue distribution, active metabolites, and long-term consequences remain open. Species differences in metabolism can affect observed half-life and target engagement.

SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. These receptors help regulate circadian rhythms and metabolic gene expression. In laboratory experiments, SR9009 binds these receptors and alters transcription of genes involved in lipid handling, glucose metabolism, and mitochondrial function. It is not a naturally occurring compound and has no approved therapeutic use. Research interest stems from its ability to modify energy metabolism in cells and animal models.

Analytical Detection and Stability

Regulatory treatment of SR9009 varies by country and region. It is not approved as a pharmaceutical, and several jurisdictions restrict its sale for human consumption. Some authorities classify it as a research chemical, a prescription-only substance, or a prohibited performance-enhancing agent in sport. Purchasers may encounter certificates of analysis, but these documents do not guarantee identity, purity, or legality. In research settings, institutional safety reviews and controlled procurement help ensure that materials are handled under appropriate oversight. The absence of harmonized rules means that legal status can change and requires verification.

Analytical identification of SR9009 typically relies on liquid chromatography coupled with tandem mass spectrometry. In biological samples, researchers first separate the compound from matrix components using protein precipitation, liquid-liquid extraction, or solid-phase extraction. High-performance liquid chromatography with ultraviolet detection and nuclear magnetic resonance spectroscopy can support structural confirmation of reference materials. Because SR9009 is a small, relatively lipophilic molecule, reverse-phase columns and acidic mobile phases are common. Laboratories often include isotope-labeled internal standards to improve quantification and to correct for ion suppression.

Sr9009 at a glance

PropertyValueNotes
Chemical classSynthetic small-molecule REV-ERB agonistNot a hormone or natural product
Primary targetsREV-ERBα and REV-ERBβNuclear receptors involved in circadian and metabolic regulation
AppearanceWhite to off-white solidTypical for purified research samples
SolubilitySoluble in DMSO and ethanol; low water solubilityLaboratory solubility depends on solvent and purity
Common synonymsSR9009; StenabolicStenabolic is a colloquial name, not a formal chemical name

Handling, Analysis, and Regulation

Analytical identification and purity assessment often use high-performance liquid chromatography with ultraviolet detection or mass spectrometry. Liquid chromatography–tandem mass spectrometry is used to detect and quantify SR9009 in biological matrices, including urine and blood, for anti-doping or pharmacokinetic studies. Nuclear magnetic resonance spectroscopy can confirm molecular structure. Stability depends on form and storage: the solid is generally more stable than solutions, and repeated freeze–thaw cycles may degrade samples. Purity is typically reported as a percentage from a certificate of analysis.

Regulatory treatment of SR9009 varies by country and context. It is not approved as a therapeutic drug by agencies such as the United States Food and Drug Administration or the European Medicines Agency. Sports authorities list it as a prohibited substance; the World Anti-Doping Agency classifies it among hormone and metabolic modulators. Legal status for personal possession or sale differs across jurisdictions, and some countries may restrict it under analog or research chemical laws. Buyers who seek verified material often rely on independent laboratory testing because online product labels may not match contents.

Related pages on this site

Background and Pharmacological Mechanism

SR9009 is a synthetic small molecule developed as a REV-ERB agonist. It binds to REV-ERBα and REV-ERBβ, nuclear receptors that help regulate circadian rhythms and metabolic gene expression. In cell and animal studies, the compound alters lipid and glucose handling and influences skeletal muscle oxidative capacity. Its exact effects in humans remain largely uncharacterized because controlled clinical trials have not been reported. The molecule is frequently described in preclinical literature as a metabolic modulator.

Research interest in SR9009 grew from studies showing improved running endurance in mice after short treatment periods. Those experiments linked the compound to increased mitochondrial content and fatty acid oxidation in muscle, but the findings come from animal models and specific dosing schedules. Independent replication has been limited, and the pathways connecting REV-ERB activation to exercise performance are still being mapped. Whether similar responses occur in humans is an open question.

Detection, Regulation, and Misconceptions

Analytical chemists detect SR9009 with liquid chromatography-tandem mass spectrometry, commonly abbreviated LC-MS/MS. Sample preparation may involve protein precipitation, liquid-liquid extraction, or solid-phase extraction before analysis. Laboratories can target the parent compound or its metabolites, depending on the matrix and the purpose of testing. Anti-doping methods require sensitive and specific assays because concentrations in biological samples can be low. Reference standards and validated methods are essential for reliable identification and quantification.

Regulatory agencies have not approved SR9009 for human therapeutic use. It is typically sold as a research chemical with labels stating that it is not for human consumption. The World Anti-Doping Agency prohibits the substance in sport, generally under the category of non-approved substances. Customs and national laws may restrict importation, sale, or possession. Product quality and legal status can vary by country and vendor, and therapeutic claims are not permitted in regulated advertising because the compound lacks approval.

Several misconceptions surround SR9009. It is often described as a SARM, a steroid, or an exercise pill, but its known target is the REV-ERB receptor family. Rodent studies have examined exercise capacity and metabolic markers, yet human outcomes remain unproven. Oral bioavailability appears low in animals, and human pharmacokinetics are not well characterized. Online products may contain impurities or different compounds, so identity and purity testing are important for research use.

Background and Mechanism

SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. It is not an approved medicine and has no established human therapeutic use. The compound appears in scientific literature as a tool for probing circadian and metabolic regulation. Online sellers often label it as a research chemical, sometimes using the nickname Stenabolic. Its chemical identity is distinct from selective androgen receptor modulators, stimulants, and peroxisome proliferator-activated receptor delta agonists. Researchers use it mainly in cell and animal experiments.

At the molecular level, SR9009 binds REV-ERBα and REV-ERBβ and alters their repressive activity on target genes. These nuclear receptors help regulate the circadian clock, lipid synthesis, glucose metabolism, and inflammatory pathways. By changing transcription, the compound can shift the timing or magnitude of downstream metabolic processes in model systems. It does not act through androgen receptors or adenosine receptors, which distinguishes it from several substances sold for athletic performance. Whether the same transcriptional changes occur in humans at tolerable exposures remains an open question because controlled human studies are lacking.

Reference notes

According to Ren Naiqiang, a contemporary who had worked under Liu's government, it was only through the promotion of Buddhism that Liu was able to stabilize his rule after the retreat to Xikang. Upon arriving in Kangding, Liu reportedly invited several famous lamas to gather at his residence to teach him scriptures and dharma. Liu would turn prayer wheels and chant mantras. After these sessions, the lamas spread the word that Liu was in fact the reincarnation of the protector Vajrapani, which greatly enhanced his reputation amongst the people of Kham.

=== Active control studies === In cases where giving a placebo to a person suffering from a disease may be unethical, "active comparator" (also known as "active control") trials may be conducted instead. In trials with an active control group, subjects are given either the experimental treatment or a previously approved treatment with known effectiveness. In other cases, sponsors may conduct an active comparator trial to establish an efficacy claim relative to the active comparator instead of the placebo in labeling.

== Available forms == The abuse-deterring effects of atropine when used as an adulterant are reasonably effective in reducing the combination's potential for recreational use. It combines the mechanisms of naloxone and paracetamol (the two more commonly used abuse-deterring agents) by increasing the likelihood of the overdose resulting in harmful and/or fatal sequelae (as does paracetamol), in addition to reliably producing unpleasant side-effects which "spoil" the opioid euphoria and discourage abusers from overdosing again following their initial experience (as does naloxone). This does not deter the use of single doses of difenoxin to potentiate another opiate, the anticholingeric activity of a single tablet is actually likely to increase the pleasurable effects of opioid use in a manner similar to combining one or more opioids with orphenadrine.

== History == In September 2005, Pfizer received a non-approvable letter from the U.S. Food and Drug Administration regarding lasofoxifene (trade name Oporia), a selective estrogen receptor modulator for the prevention of osteoporosis. In January 2008, Ligand Pharmaceuticals, through its marketing partner, Pfizer, submitted a New Drug Application for lasofoxifene, which is expected to be marketed under the tradename Fablyn. Lasofoxifene was approved in the EU under the brand name Fablyn by the EMEA in March 2009.

=== COVID-19 === In 2021, dimethyl fumarate was evaluated as a treatment for COVID-19 as part of the RECOVERY Trial in the UK. The results of the trial found that dimethyl fumarate did not significantly improve clinical outcomes in hospitalized COVID-19 patients.

Sources: en.wikipedia.org

Notes from published material

== Nutrition == Some vitamins and other trace nutrients are lost, particularly from vegetables, partially by enzyme action during cooking and partially due to heat degradation. When vegetables are cooked at higher temperatures these enzymes are rapidly denatured and have less time to act during cooking. Since slow cookers work at temperatures well below boiling point and do not rapidly denature enzymes, vegetables tend to lose trace nutrients. Blanched vegetables, having been exposed to very hot water, have already had these enzymes rendered largely ineffective, so a blanching or sauteing pre-cook stage leaves more vitamins intact. This is often a smaller nutrient loss than over-boiling and can be lessened to an extent by not removing the lid until the food is done. Slow cookers should not be used to cook dried kidney beans and other legume seeds. These foods contain a highly toxic lectin, phytohemagglutinin, making as few as four raw beans toxic. This lectin is only deactivated by long soaking, then boiling in fresh water at 100 °C (212 °F) for at least thirty minutes. Information published by the United States Food and Drug Administration states that slow cookers should not be used to cook bean containing dishes. Commercially canned beans are fully cooked and are safe to use. Pressure cooking also deactivates the lectins.

Lorazepam, sold under the brand name Ativan among others, is a medication of the benzodiazepine and depressant category. It inhibits activity of the central nervous system, and has anxiolytic and hypnotic effects. It is indicated for the short term treatment of anxiety (including anxiety disorders), insomnia, severe agitation, active seizures including status epilepticus, alcohol withdrawal, and chemotherapy-induced nausea and vomiting. It is also used during surgery to interfere with memory formation, to sedate those who are being mechanically ventilated, and, along with other treatments, for acute coronary syndrome due to cocaine use. It can be given orally (by mouth), transdermally (on the skin via a topical gel or patch), intravenously (injection into a vein), or intramuscularly (injection into a muscle). When given by injection, onset of effects is between one and thirty minutes and effects last for up to a day. Common side effects include weakness, sleepiness, dizziness, decreased alertness, decreased memory formation, low blood pressure, and a decreased effort to breathe. When given intravenously, the person is typically closely monitored. Among those who are depressed, there may be an increased risk of suicide. Drug tolerance may occur, especially after long-term use, where increasingly larger doses are required to achieve the same effect. Its use is highly liable to physical dependence and psychological dependence, and sudden stop after long-term use can cause symptoms of benzodiazepine withdrawal. Older people more often develop adverse effects.

On the weekend of September 23–25, 2022, a delegation of the Grand Lodge of Veracruz, from Veracruz, Veracruz, traveled to Havana, where the Grand Lodge of Cuba recognized that body as "regular and correct" in a ceremony at the National Temple. Grand Master Alfonso Vidal, with the Grand Commander of the Supreme Council of Cuba, José Ramón Viñas Alonso, presented certificates of friendship and recognition to the Mexican delegation. In what was called an act of fraternal friendship, the Grand Lodge of Veracruz invited the Grand Master Alfonso Vidal to tour their Grand Lodge in Mexico and participate in a Masonic ceremony there. On December 5, 2022, the National Temple hosted the 163rd anniversary celebration of the founding of the Grand Lodge of Colon in 1859. Grand Orator Luis Steve Ocaña guided the congregation through the history of Cuban Freemasonry since the 19th century, and told the congregation of hundreds of Freemasons in his liturgy that: "Today, the fight for the homeland is with the most important weapon that Freemasons carry, which is the most lofty thought with which we must act to stop seeing everywhere the lament of the loss of values in society.... I believe that we masons should talk about politics, since it is the fundamental rule that governs society, we must talk and, in addition, look for a way to do politics." Days later, Alfonso Vidal was interrogated again by Agent Poll from the State Security Unit. This interrogation lasted for twelve hours.

=== Wound healing === In root and tuber crops such as potatoes and carrots, curing refers to waiting for the healing of wounds by periderm formation. Doing so prolongs shelf life and reduces water loss.

Sources: en.wikipedia.org

Frequently asked questions

What is SR9009?

It is a synthetic research compound that activates REV-ERB nuclear receptors. It is not an approved drug or dietary supplement. Most information comes from cell and animal studies.

How does SR9009 work?

It binds REV-ERBα and REV-ERBβ and changes transcription of metabolic genes. This can affect circadian rhythm, lipid use, and mitochondrial function. The full downstream effects are still under study.

Is SR9009 proven to improve human performance?

No. Some rodent studies show increased endurance, but controlled human trials are lacking. Claims about human performance are not established by published evidence.

How is SR9009 measured in samples?

The most common approach is liquid chromatography-tandem mass spectrometry, often after extraction from blood, urine, or tissue. Ultraviolet detection and nuclear magnetic resonance spectroscopy are used mainly for reference material characterization. Isotope-labeled internal standards improve accuracy.

Network